```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 4120 Enrolled Bill (ENR)]

        S.4120

                    One Hundred Seventeenth Congress

                                 of the

                        United States of America

                          AT THE SECOND SESSION

           Begun and held at the City of Washington on Monday,
          the third day of January, two thousand and twenty two

                                 An Act

 
 To maximize discovery, and accelerate development and availability, of 
     promising childhood cancer treatments, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
    This Act may be cited as the ``Childhood Cancer Survivorship, 
Treatment, Access, and Research Reauthorization Act of 2022'' or the 
``Childhood Cancer STAR Reauthorization Act''.
SEC. 2. REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT.
    (a) Children's Cancer Biorepositories.--Section 417E of the Public 
Health Service Act (42 U.S.C. 285a-11) is amended--
        (1) in subsection (a)--
            (A) in paragraph (2)(A), by inserting before the period at 
        the end of the second sentence the following: ``, such as 
        collected samples of both solid tumor cancer and paired 
        samples'';
            (B) in paragraph (9), by striking ``Childhood Cancer 
        Survivorship, Treatment, Access, and Research Act of 2018'' and 
        inserting ``Childhood Cancer Survivorship, Treatment, Access, 
        and Research Reauthorization Act of 2022'';
            (C) by redesignating paragraph (10) as paragraph (11); and
            (D) by inserting after paragraph (9) the following:
        ``(10) Report on researcher access to children's cancer 
    biorepository samples.--Not later than 2 years after the date of 
    enactment of the Childhood Cancer Survivorship, Treatment, Access, 
    and Research Reauthorization Act of 2022, the Director of NIH 
    shall--
            ``(A) conduct a review of the procedures established under 
        paragraph (2)(C) and other policies or procedures related to 
        researcher access to such biospecimens to identify any 
        opportunities to reduce administrative burden, consistent with 
        paragraph (2)(D), in a manner that protects personal privacy to 
        the extent required by applicable Federal and State privacy 
        law, at a minimum; and
            ``(B) submit to the Committee on Health, Education, Labor, 
        and Pensions of the Senate and the Committee on Energy and 
        Commerce of the House of Representatives a report on the 
        findings of the review under subparagraph (A) and whether the 
        Director of NIH plans to make any changes to the policies or 
        procedures considered in such review, based on such 
        findings.''; and
        (2) in subsection (d), by striking ``2019 through 2023'' and 
    inserting ``2024 through 2028''.
    (b) Cancer Survivorship Programs.--Section 201 of the Childhood 
Cancer Survivorship, Treatment, Access, and Research Act of 2018 
(Public Law 115-180) is amended--
        (1) in subsection (a)--
            (A) in the subsection heading, by striking ``Pilot Programs 
        to Explore'' and inserting ``Research to Evaluate''
            (B) in paragraph (1)--
                (i) by striking ``may make awards to eligible entities 
            to establish pilot programs'' and inserting ``shall, as 
            appropriate, make awards to eligible entities to conduct or 
            support research'';
                (ii) by striking ``model systems'' and inserting 
            ``approaches'';
                (iii) by inserting ``and adolescent'' after 
            ``childhood''; and
                (iv) by striking ``evaluation of models for'';
            (C) in paragraph (2)--
                (i) in subparagraph (A), in the matter preceding clause 
            (i), by inserting ``within the existing peer review 
            process,'' after ``practicable,''; and
                (ii) in subparagraph (B)(v), by striking ``in treating 
            survivors of childhood cancers'' and inserting ``in 
            carrying out the activities described in paragraph (1)''; 
            and
            (D) in paragraph (3)(B)(v), by striking ``design of systems 
        for the effective transfer of treatment information and care 
        summaries from cancer care providers to other health care 
        providers'' and inserting ``design tools to support the secure 
        electronic transfer of treatment information and care summaries 
        between health care providers or, as applicable and 
        appropriate, longitudinal childhood cancer survivorship 
        cohorts''; and
        (2) in subsection (b)--
            (A) in each of paragraphs (1) and (2), by striking ``date 
        of enactment of this Act'' and inserting ``date of enactment of 
        the Childhood Cancer Survivorship, Treatment, Access, and 
        Research Reauthorization Act of 2022''; and
            (B) in paragraph (1)--
                (i) by striking subparagraphs (A) and (C);
                (ii) by redesignating subparagraph (B) as subparagraph 
            (A); and
                (iii) by adding at the end the following:
            ``(B) recommendations for enhancing or promoting activities 
        of the Department of Health and Human Services related to 
        workforce development for health care providers who provide 
        psychosocial care to pediatric cancer patients and 
        survivors.''.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
```